There is a need for second line therapies in patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals of brivanib in phase 2 studies reported herein have yet to be confirmed in phase 3 trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development 30 strategies in this setting.
- Received January 31, 2012.
- Accepted February 9, 2012.
- Copyright © 2012, American Association for Cancer Research.